ORM-1023 / Orum Therap - LARVOL DELTA

The "TPD² Evolution" Begins in Full Swing… GSPT1 Target Pipeline Unveiled [Google translation] (HIT News) - "Preclinical studies have shown that ORM‑1153 selectively delivers a GSPT1 degradation inducer to tumor cells through this antibody, and exhibits tumor-selective cytotoxicity up to 1,000 times higher than existing small molecule degraders (CC-90009) or single payloads (SMol006), raising expectations before entering clinical trials. In addition, Orum announced that it has confirmed potent anti-tumor activity in preclinical studies of ORM-1023, a protein degradation-based therapeutic currently in development for small cell lung cancer (SCLC) and neuroendocrine tumors....The company is also accelerating development of ORM-1153, aiming for an IND submission next year, and has announced key data to be presented at ASH later this year."

IND • Preclinical • Hematological Malignancies • Neuroendocrine Tumor • Small Cell Lung Cancer

[IPO Alert][Orum Therapeutics] No Good News for Several Years After IPO [Google translation] (PRESS9) - "Orum therapeutics announced that it plans to transfer technology for ORM-5029, which was suspended due to toxicity issues in the low-dose phase 1 clinical trial, in 2026....In addition, Orom Therapeutics announced that it plans to transfer ORM-1023 and ORM-1153, which are still in the discovery stage, in 2026. It seems premature to discuss technology transfer when the substance has not been confirmed."

Commercial • Hematological Malignancies • HER2 Breast Cancer • Small Cell Lung Cancer

Orum Therapeutics invests 30 billion won in research funds for 3 types including ’ORM-5029’ [Google translation] (Medipana) - "It plans to raise the funds through a public offering on the KOSDAQ market in November. According to the Financial Supervisory Service's Electronic Disclosure System on the 7th, Orum Therapeutics plans to use approximately 30 billion won in funds for three projects under research and development, 'ORM-5029', 'ORM-1023', and 'ORM-1153', by 2026. Specifically, it plans to invest 11.3 billion won in 'ORM-5029', a metastatic breast cancer treatment, 9 billion won in 'ORM-1023', a small cell lung cancer treatment, and 9.8 billion won in 'ORM-1153', a blood cancer treatment....The plan is to procure funds for research and development through a KOSDAQ listing scheduled for November. According to the securities report submitted by Orum Therapeutics on the 2nd, the number of shares being offered through this KOSDAQ listing is 3 million, and the range of the desired public offering price per share is 30,000 to 36,000 won."

Financing • Breast Cancer • Hematological Malignancies • HER2 Breast Cancer • Lung Cancer • Oncology • Small Cell Lung Cancer • Solid Tumor

Orum Therapeutics invests 30 billion won in research funds for 3 types including 'ORM-5029' [Google translation] (Medipana) - "The company's lead pipeline ORM-5029 is currently undergoing phase 1 clinical trials in the United States, and the company plans to transfer the asset technology after the phase 1 clinical trial is completed...'it is expected that a technology transfer contract can be signed in 2026.'....In addition, the company announced that it is planning an asset technology transfer for 'ORM-1153', which is currently in the preclinical stage, at the IND stage before entering phase 1 clinical trials in 2026, and an asset technology transfer for 'ORM-1023', which will also be conducted jointly with a partner at the IND stage before entering phase 1 clinical trials in 2026."

Licensing / partnership • New P1 trial • Trial status • Breast Cancer • Lung Cancer • Oncology • Small Cell Lung Cancer • Solid Tumor • HER-2